Sponsor: Boston Medical Center Grayken Center for Addiction TA, Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS)
This training will cover evidence-based strategies for initiating buprenorphine treatment within ambulatory care practices. Special attention will be directed towards effective measures that support the transition of patients using illicitly manufactured fentanyl onto prescribed buprenorphine.
NOTE: This training is 60 minutes long. There will be an optional 30-minute Q&A session following the training, which will not count for credit.
Medical providers, nurses, social workers, Licensed Alcohol and Drug Counselors (LADC), Certified Alcohol/Drug Counselors (CADC), Community Health Workers (CHW), recovery coaches, counselors, Licensed Mental health Counselors (LMHC), and others working in addiction medicine.
At the end of this training, participants will have the knowledge necessary to:
- Describe the prevalence of illicitly manufactured fentanyl in the US drug supply.
- Explain the major pharmacologic properties of both fentanyl and buprenorphine.
- Recall at least two “tools” that can help guide the process of starting buprenorphine treatment.
- Identify at least three medications that have been proven to support management of withdrawal symptoms during the buprenorphine initiation process.
For more information and to register click here
To register you must create an account.
- October 3, 2023
- 12:00 pm - 1:00 pm
- virtual via Zoom
- no costs